Home
Yervoy

Yervoy Market Share Analysis for November 2025

opdivo® (nivolumab) is a prescription medication that treats certain types of cancer. read the indications, side effects, and more. please see indication and important safety information.

Health > Pharmacy

Domainyervoy.com

Year Founded--

Employees51 - 200

Annual Revenue$15M - $25M

Yervoy

Yervoy (including company regionals)

yervoy.com

See more website traffic and engagement information

Yervoy Revenue up to November 2025 is 15M - 25M

revenue generated by Yervoy top domains

Yervoy top domains revenue over 3 years

Revenue for Yervoy top domains

yervoy.com15M - 25M

See more with Sales Intelligence

Total visits to Yervoy's top domains

Understand Yervoy market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Yervoy's top domains

Analyze Yervoy engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Yervoy's top domains

See how Yervoy keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Yervoy top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Yervoy

These are the website technologies, by industry, used by Yervoy top domains

Conversion & Analytics (9)

Google Analytics

Advertising (4)

DoubleClick

Payment & Currencies (4)

Stripe

Marketing (2)

Google Marketing Platform

More Technologies

9

See all

News & Signals from Yervoy

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOpdivo partnered with Yervoy® on Sep 6th '20.“Bristol Myers Squibb introduced the first immunotherapy combination to patients with renal cell carcinoma in the EU with the approval of Opdivo plus Yervoy, which has shown durable, long-term survival in the pivotal CheckMate -214 trial.